What question did this study set out to answer?

This research evaluates clinical outcomes in chronic myelomonocytic leukemia (CMML) across trials submitted to the FDA.

December 8, 2025BloodOpen Access

Chronic myelomonocytic leukemia: Clinical outcomes from clinical trials submitted to the FDA over the past 25 years

View Full Paper

Ask AI

Bookmark

Authors

Clinical trials report overall survival and response rates in chronic myelomonocytic leukemia, indicating limited treatment efficacy.

This research evaluates clinical outcomes in chronic myelomonocytic leukemia (CMML) across trials submitted to the FDA.
Reviewed phase 2 and 3 trials for CMML from FDA submissions between 2000 and 2025.
Conducted patient-level analyses based on WHO diagnostic criteria.
Calculated overall survival (OS) and overall response rates (ORR) using standard definitions.
Identified 10 trials with 196 patients treated for CMML using various hypomethylating agents.
Median overall survival was 20.4 months with significant differences based on treatment type.
Patients achieving complete response had a median OS of 85.8 months compared to 15.7 months for those who did not.

Li et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark